Cardiovascular DiseasesNCT00005679
Pathobiological Determinants of Atherosclerosis in Youth (PDAY)
An observational study of Cardiovascular Diseases and Atherosclerosis, run by National Heart, Lung, and Blood Institute (NHLBI).
Trial summary
To conduct a multicenter prevalence survey for characterizing pathologically the extent of atherosclerosis in the aortas and coronary arteries of young persons dying from accidental causes, suicide, or homicide. Read more about this study
- Who is it for?
- Ages 15 to 34 years
- Conditions the study is for
- Cardiovascular Diseases, Atherosclerosis, Heart Diseases
- How many people
- Not given
- Where
- No sites listed yet
- Study dates
- Jun 1985to Jul 1993
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 15 to 34 years
- All sexes
- No healthy volunteers
- Child, Adult
No eligibility criteria
About this study
To conduct a multicenter prevalence survey for characterizing pathologically the extent of atherosclerosis in the aortas and coronary arteries of young persons dying from accidental causes, suicide, or homicide.
Read the detailed description
BACKGROUND:
The International Atherosclerosis Project (IAP) quantified atherosclerosis of the aorta and coronary arteries in over 31,000 persons age 10 to 69 who died between 1960 and 1965 in fifteen cities and countries throughout the world. The IAP established that the average severity of atherosclerosis differed widely in many parts of the world and that the differences correlated with mortality from ischemic heart disease. It also demonstrated that the fatty streaks of childhood were prevalent and severe in both boys and girls. Fibrous plaques generally first appeared between the ages of 20 and 30 and in proportion to the prevalence of ischemic disease in the adult population. Since the results of the IAP were first published in 1968, research into atherosclerosis has changed greatly from gross and microscopic morphological methods to manipulation of experimental animals, in vitro culture of arterial wall cells, and the application of micro-chemical, physical chemical, and immunological techniques to tissues.
The use of these newer techniques made it possible to test the hypothesis that a series of changes in the fatty streak between the ages of fifteen and twenty-five lead to the typical fibrous plaque and to test the hypothesis that lesions other than fatty streaks precede and may progress to fibrous plaques. The study also tested associations of the established risk factors for atherosclerosis with early stages of lesion progression as seen in young persons.
The protocol for this study served as the basis of the protocol developed by the World Health Organization (WHO) Committee on Pathobiological Determinants of Atherosclerosis in Youth. It was planned to incorporate this study into the WHO study so that cross-cultural and geographic factors could be evaluated in populations with higher and lower incidence of atherosclerosis.
DESIGN NARRATIVE:
A common protocol was followed for collecting risk factor data and coronary arteries and aortas from approximately 1,000 autopsies per year for three years. Specimens were collected and preserved in a standardized way at each collection center. Data management and statistical analysis were conducted at the University of Texas in San Antonio. The unit at Louisiana State University was composed of three central laboratories: the lipid biochemistry center; the coronary heart disease risk factor center; and a gross morphology center. The morphometry central laboratory was located at Ohio State University. Administration and coordination were directed from the University of Chicago and the University of Illinois.
In addition to serving as collection centers, many of the centers carried out individual research projects. At the University of Alabama in Birmingham, two separate but related investigations were conducted: Dr. Miller analyzed the various collagens by solubilizing them as peptide fractions and isolating the peptides via chromatography; Dr. Gay used monoclonal antibodies to define the distribution of the various collagens in atheromatous lesions. At the West Virginia University under Dr. Jagannathan, there were studies on isomeric fatty acids and proteoglycans. Dr. Reichenbach at the University of Washington studied the distribution of immunocytochemical markers of smooth muscle cell differentiation and leukocyte subpopulations in the coronary arteries as well as searched for viral DNA in plaques. At Baylor, the three-dimensional distribution of lipid inclusions, macrophages, and smooth muscle cells in coronary arteries were determined by digital fluorescence. Dr. Mergner of the University of Maryland collected specimens in the immediate autopsy program which provided specimens free of autolysis. He also performed transmission and scanning electron microscopy, X-ray microanalysis, lipid analysis, and immunofluorescence and immunoperoxidase procedures to define calcium content and cytoskeletal components. Dr. Virmani at Vanderbilt determined the role of biogenic amines such as histamine, serotonin, and catecholamines in atherosclerosis and correlated the content of amines with the presence of mast cells in the adventitia.
In 1988, two regular research grants were awarded as part of this multicenter study. The grant at the Southwest Foundation for Biomedical Research determined the genotypes for each subject with respect to restriction fragment length polymorphisms in apolipoprotein and LDL receptor genes using Southern blot analyses of DNA from liver samples sent from each collection center. It also typed the subjects for apo E isoform genotypes using oligonucleotide probes. The grant at Ohio State University correlated 3-D coronary axial geometry and pathology.
Some of the major questions addressed by the study included: whether some or all fatty streaks progressed to fibrous plaques and the transitional lesions; the morphometric and biochemical lesion changes indicated by progression; the frequency and features of insudative and proliferative lesions which may portend progressive disease; sex differences in lesions; whether immune complexes or viral infections were implicated.
In FY 1991, six grants were awarded under the title "Risk Factors in Early Human Atherogenesis" (RFEHA). The purpose was to extend the ongoing PDAY and to : obtain an adequate number of female cases so that risk factor associations could be accurately detected and studied; to increase the power of the study in general to detect associations of risk factors with raised lesions, which began to appear in this age group; and to increase the power of the study to detect genetic influences on atherosclerosis. REFHA added 1,400 new specimens to the 1,800 cases already collected in PDAY to achieve approximately 3,000 total specimens. Emphasis was placed on female cases and those that provided the best opportunity to study transition lesions between fatty streaks and fibrous plaques.
In 1998, the NHLBI awarded R24HL60808 for five years to provide and maintain an archive of human cardiovascular and other tissues which can be used by other United States and international investigators to study human atherosclerosis. The investigators, as part of PDAY and RFEHA, have assembled autopsy material (mostly of aorta and coronary artery, but with other tissues including liver, serum, and adipose tissue) from over 3,000 Black and white males and females. These were from autopsies on individuals ages 15 to 34 and obtained within 48 hours of death. The grant for the cardiovascular specimen and data library was renewed through July 2007.
- Conditions
- Cardiovascular Diseases, Atherosclerosis, Heart Diseases, Coronary Disease, Coronary Arteriosclerosis
- Medical subject headings
- Cardiovascular Diseases, Atherosclerosis, Heart Diseases, Coronary Disease, Coronary Artery Disease
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 May 2000 (estimated)
- Study startJun 1985
- Primary completionJul 1993
- Study completionJul 1993
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (52)Papers the sponsor has linked to this study.
- Other trials for Cardiovascular DiseasesStudies of the same condition, open and under way.
- More trials run by National Heart, Lung, and Blood Institute (NHLBI)The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
Sponsor and investigators
- Sponsor type
- US National Institutes of Health
- Investigators
- Arthur Chandler, Augusta UniversityJ. Cornhill, Ohio State UniversityAsaad Daoud, Albany Medical CollegeMorton Friedman, Ohio State UniversitySteffen Gay, University of Alabama at BirminghamJames Hixson, Southwest Foundation for Biomedical ResearchSinganallur Jagannathan, West Virginia University Medical CenterC. McMahan, University of Texas
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00005679
- Sponsor's protocol ID
- 1049
- Other IDs
- R10HL033772
- Status last verified
- Jan 2008
- First submitted
- 25 May 2000
- Last updated
- 18 Feb 2016
- Results posted
- No
Publications
Relationship of atherosclerosis in young men to serum lipoprotein cholesterol concentrations and smoking. A preliminary report from the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. JAMA. 1990 Dec 19;264(23):3018-24. doi: 10.1001/jama.1990.03450230054029.
PubMed 2243430Hixson JE, McMahan CA, McGill HC Jr, Strong JP. Apo B insertion/deletion polymorphisms are associated with atherosclerosis in young black but not young white males. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Arterioscler Thromb. 1992 Sep;12(9):1023-9. doi: 10.1161/01.atv.12.9.1023.
PubMed 1525116Hixson JE. Apolipoprotein E polymorphisms affect atherosclerosis in young males. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Arterioscler Thromb. 1991 Sep-Oct;11(5):1237-44. doi: 10.1161/01.atv.11.5.1237.
PubMed 1680392Wissler RW. Theories and new horizons in the pathogenesis of atherosclerosis and the mechanisms of clinical effects. Arch Pathol Lab Med. 1992 Dec;116(12):1281-91.
PubMed 1456873Wissler RW. USA Multicenter Study of the pathobiology of atherosclerosis in youth. Ann N Y Acad Sci. 1991;623:26-39. doi: 10.1111/j.1749-6632.1991.tb43716.x. No abstract available.
PubMed 2042833Wissler RW, Vesselinovitch D, Komatsu A. The contribution of studies of atherosclerotic lesions in young people to future research. Ann N Y Acad Sci. 1990;598:418-34. doi: 10.1111/j.1749-6632.1990.tb42313.x. No abstract available.
PubMed 2248455Wissler RW, Vesselinovitch D. An update on the pathogenesis of atherosclerosis (principles of prevention, intervention, retardation, and regression). Hawaii Med J. 1990 Jul;49(7):237-40, 261.
PubMed 2397997McGill HC Jr, Strong JP, Tracy RE, McMahan CA, Oalmann MC. Relation of a postmortem renal index of hypertension to atherosclerosis in youth. The Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Arterioscler Thromb Vasc Biol. 1995 Dec;15(12):2222-8. doi: 10.1161/01.atv.15.12.2222.
PubMed 7489246Cornhill JF, Herderick EE, Vince DG. The clinical morphology of human atherosclerotic lesions. Lessons from the PDAY Study. Pathobiological Determinants of Atherosclerosis in Youth. Wien Klin Wochenschr. 1995;107(18):540-3.
PubMed 7483640McGill HC Jr, McMahan CA, Malcom GT, Oalmann MC, Strong JP. Relation of glycohemoglobin and adiposity to atherosclerosis in youth. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Arterioscler Thromb Vasc Biol. 1995 Apr;15(4):431-40. doi: 10.1161/01.atv.15.4.431.
PubMed 7749853Strong JP. Natural history and risk factors for early human atherogenesis. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Clin Chem. 1995 Jan;41(1):134-8.
PubMed 7813067Wissler RW. New insights into the pathogenesis of atherosclerosis as revealed by PDAY. Pathobiological Determinants of Atherosclerosis in Youth. Atherosclerosis. 1994 Aug;108 Suppl:S3-20. doi: 10.1016/0021-9150(94)90149-x.
PubMed 7802726Natural history of aortic and coronary atherosclerotic lesions in youth. Findings from the PDAY Study. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Arterioscler Thromb. 1993 Sep;13(9):1291-8. doi: 10.1161/01.atv.13.9.1291.
PubMed 8364013Kuo CC, Grayston JT, Campbell LA, Goo YA, Wissler RW, Benditt EP. Chlamydia pneumoniae (TWAR) in coronary arteries of young adults (15-34 years old). Proc Natl Acad Sci U S A. 1995 Jul 18;92(15):6911-4. doi: 10.1073/pnas.92.15.6911.
PubMed 7624342Miller EJ, Malcom GT, McMahan CA, Strong JP. Atherosclerosis in young white males: arterial collagen and cholesterol. Matrix. 1993 Jul;13(4):289-96. doi: 10.1016/s0934-8832(11)80024-7.
PubMed 8412986
Study at a glance
From the registry record, last updated by the sponsor on 18 Feb 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pathobiological Determinants of Atherosclerosis in Youth (PDAY)
- ClinicalTrials.gov ID
- NCT00005679
- Acronym / sponsor ID
- 1049
- Conditions
- Cardiovascular Diseases, Atherosclerosis, Heart Diseases, Coronary Disease, Coronary Arteriosclerosis
- Study type
- Observational
- Recruitment status
- Completed
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)US National Institutes of Health
- Study start
- Jun 1985
- Primary completion
- Jul 1993 (actual)
- Study completion
- Jul 1993 (actual)
- First posted
- 26 May 2000 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To conduct a multicenter prevalence survey for characterizing pathologically the extent of atherosclerosis in the aortas and coronary arteries of young persons dying from accidental causes, suicide, or homicide.
Detailed description
BACKGROUND:
The International Atherosclerosis Project (IAP) quantified atherosclerosis of the aorta and coronary arteries in over 31,000 persons age 10 to 69 who died between 1960 and 1965 in fifteen cities and countries throughout the world. The IAP established that the average severity of atherosclerosis differed widely in many parts of the world and that the differences correlated with mortality from ischemic heart disease. It also demonstrated that the fatty streaks of childhood were prevalent and severe in both boys and girls. Fibrous plaques generally first appeared between the ages of 20 and 30 and in proportion to the prevalence of ischemic disease in the adult population. Since the results of the IAP were first published in 1968, research into atherosclerosis has changed greatly from gross and microscopic morphological methods to manipulation of experimental animals, in vitro culture of arterial wall cells, and the application of micro-chemical, physical chemical, and immunological techniques to tissues.
The use of these newer techniques made it possible to test the hypothesis that a series of changes in the fatty streak between the ages of fifteen and twenty-five lead to the typical fibrous plaque and to test the hypothesis that lesions other than fatty streaks precede and may progress to fibrous plaques. The study also tested associations of the established risk factors for atherosclerosis with early stages of lesion progression as seen in young persons.
The protocol for this study served as the basis of the protocol developed by the World Health Organization (WHO) Committee on Pathobiological Determinants of Atherosclerosis in Youth. It was planned to incorporate this study into the WHO study so that cross-cultural and geographic factors could be evaluated in populations with higher and lower incidence of atherosclerosis.
DESIGN NARRATIVE:
A common protocol was followed for collecting risk factor data and coronary arteries and aortas from approximately 1,000 autopsies per year for three years. Specimens were collected and preserved in a standardized way at each collection center. Data management and statistical analysis were conducted at the University of Texas in San Antonio. The unit at Louisiana State University was composed of three central laboratories: the lipid biochemistry center; the coronary heart disease risk factor center; and a gross morphology center. The morphometry central laboratory was located at Ohio State University. Administration and coordination were directed from the University of Chicago and the University of Illinois.
In addition to serving as collection centers, many of the centers carried out individual research projects. At the University of Alabama in Birmingham, two separate but related investigations were conducted: Dr. Miller analyzed the various collagens by solubilizing them as peptide fractions and isolating the peptides via chromatography; Dr. Gay used monoclonal antibodies to define the distribution of the various collagens in atheromatous lesions. At the West Virginia University under Dr. Jagannathan, there were studies on isomeric fatty acids and proteoglycans. Dr. Reichenbach at the University of Washington studied the distribution of immunocytochemical markers of smooth muscle cell differentiation and leukocyte subpopulations in the coronary arteries as well as searched for viral DNA in plaques. At Baylor, the three-dimensional distribution of lipid inclusions, macrophages, and smooth muscle cells in coronary arteries were determined by digital fluorescence. Dr. Mergner of the University of Maryland collected specimens in the immediate autopsy program which provided specimens free of autolysis. He also performed transmission and scanning electron microscopy, X-ray microanalysis, lipid analysis, and immunofluorescence and immunoperoxidase procedures to define calcium content and cytoskeletal components. Dr. Virmani at Vanderbilt determined the role of biogenic amines such as histamine, serotonin, and catecholamines in atherosclerosis and correlated the content of amines with the presence of mast cells in the adventitia.
In 1988, two regular research grants were awarded as part of this multicenter study. The grant at the Southwest Foundation for Biomedical Research determined the genotypes for each subject with respect to restriction fragment length polymorphisms in apolipoprotein and LDL receptor genes using Southern blot analyses of DNA from liver samples sent from each collection center. It also typed the subjects for apo E isoform genotypes using oligonucleotide probes. The grant at Ohio State University correlated 3-D coronary axial geometry and pathology.
Some of the major questions addressed by the study included: whether some or all fatty streaks progressed to fibrous plaques and the transitional lesions; the morphometric and biochemical lesion changes indicated by progression; the frequency and features of insudative and proliferative lesions which may portend progressive disease; sex differences in lesions; whether immune complexes or viral infections were implicated.
In FY 1991, six grants were awarded under the title "Risk Factors in Early Human Atherogenesis" (RFEHA). The purpose was to extend the ongoing PDAY and to : obtain an adequate number of female cases so that risk factor associations could be accurately detected and studied; to increase the power of the study in general to detect associations of risk factors with raised lesions, which began to appear in this age group; and to increase the power of the study to detect genetic influences on atherosclerosis. REFHA added 1,400 new specimens to the 1,800 cases already collected in PDAY to achieve approximately 3,000 total specimens. Emphasis was placed on female cases and those that provided the best opportunity to study transition lesions between fatty streaks and fibrous plaques.
In 1998, the NHLBI awarded R24HL60808 for five years to provide and maintain an archive of human cardiovascular and other tissues which can be used by other United States and international investigators to study human atherosclerosis. The investigators, as part of PDAY and RFEHA, have assembled autopsy material (mostly of aorta and coronary artery, but with other tissues including liver, serum, and adipose tissue) from over 3,000 Black and white males and females. These were from autopsies on individuals ages 15 to 34 and obtained within 48 hours of death. The grant for the cardiovascular specimen and data library was renewed through July 2007.
Study design
Who may qualify
- Ages
- 15 to 34 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Not reported in the source record.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Feb 2016.
- Background: PubMed 2243430Relationship of atherosclerosis in young men to serum lipoprotein cholesterol concentrations and smoking. A preliminary report from the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. JAMA. 1990 Dec 19;264(23):3018-24. doi: 10.1001/jama.1990.03450230054029.
- Background: PubMed 1525116Hixson JE, McMahan CA, McGill HC Jr, Strong JP. Apo B insertion/deletion polymorphisms are associated with atherosclerosis in young black but not young white males. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Arterioscler Thromb. 1992 Sep;12(9):1023-9. doi: 10.1161/01.atv.12.9.1023.
- Background: PubMed 1680392Hixson JE. Apolipoprotein E polymorphisms affect atherosclerosis in young males. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Arterioscler Thromb. 1991 Sep-Oct;11(5):1237-44. doi: 10.1161/01.atv.11.5.1237.
- Background: PubMed 1456873Wissler RW. Theories and new horizons in the pathogenesis of atherosclerosis and the mechanisms of clinical effects. Arch Pathol Lab Med. 1992 Dec;116(12):1281-91.
- Background: PubMed 2042833Wissler RW. USA Multicenter Study of the pathobiology of atherosclerosis in youth. Ann N Y Acad Sci. 1991;623:26-39. doi: 10.1111/j.1749-6632.1991.tb43716.x. No abstract available.
- Background: PubMed 2248455Wissler RW, Vesselinovitch D, Komatsu A. The contribution of studies of atherosclerotic lesions in young people to future research. Ann N Y Acad Sci. 1990;598:418-34. doi: 10.1111/j.1749-6632.1990.tb42313.x. No abstract available.
- Background: PubMed 2397997Wissler RW, Vesselinovitch D. An update on the pathogenesis of atherosclerosis (principles of prevention, intervention, retardation, and regression). Hawaii Med J. 1990 Jul;49(7):237-40, 261.
- Background: PubMed 7489246McGill HC Jr, Strong JP, Tracy RE, McMahan CA, Oalmann MC. Relation of a postmortem renal index of hypertension to atherosclerosis in youth. The Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Arterioscler Thromb Vasc Biol. 1995 Dec;15(12):2222-8. doi: 10.1161/01.atv.15.12.2222.
- Background: PubMed 7483640Cornhill JF, Herderick EE, Vince DG. The clinical morphology of human atherosclerotic lesions. Lessons from the PDAY Study. Pathobiological Determinants of Atherosclerosis in Youth. Wien Klin Wochenschr. 1995;107(18):540-3.
- Background: PubMed 7749853McGill HC Jr, McMahan CA, Malcom GT, Oalmann MC, Strong JP. Relation of glycohemoglobin and adiposity to atherosclerosis in youth. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Arterioscler Thromb Vasc Biol. 1995 Apr;15(4):431-40. doi: 10.1161/01.atv.15.4.431.
- Background: PubMed 7813067Strong JP. Natural history and risk factors for early human atherogenesis. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Clin Chem. 1995 Jan;41(1):134-8.
- Background: PubMed 7802726Wissler RW. New insights into the pathogenesis of atherosclerosis as revealed by PDAY. Pathobiological Determinants of Atherosclerosis in Youth. Atherosclerosis. 1994 Aug;108 Suppl:S3-20. doi: 10.1016/0021-9150(94)90149-x.
Related trials for Cardiovascular Diseases
Active, not recruiting
Developing a Learning COmmunity to Increase eNgagemeNt and Enrollment in Cardiovascular Clinical Trials (CONNECT)
Cardiovascular Diseases, Hypertension
RecruitingObservational study
Cardiovascular Disease Progression in Survivors of Community Acquired Pneumonia and Lung Infection by Covid-19.
Pneumonia, Community-Acquired, COVID-19 Pneumonia
RecruitingObservational study
The CACHE Study: Coronary Artery Care in HaEmophilia
Haemophilia, Cardiovascular Diseases
Recruiting
NightWare and Cardiovascular Health in Women With PTSD
Post Traumatic Stress Disorder, Cardiovascular Diseases
RecruitingPhase 1/2
Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT)
Hereditary Hemorrhagic Telangiectasia (HHT), Osler Weber Rendu Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Arthur Chandler
Augusta University
J. Cornhill
Ohio State University
Asaad Daoud
Albany Medical College
Questions about this trial
What is this clinical trial studying?
An observational study of Cardiovascular Diseases and Atherosclerosis, run by National Heart, Lung, and Blood Institute (NHLBI).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Feb 2016. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00005679, which also lists 52 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Feb 2016; AzTrials last refreshed its copy on 7 Nov 2026.